What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Fungal Infection Diagnosis Market Size, Share, Growth and Industry analysis, By Type (Galactomannan Test, (1 to 3)-?-D-glucan Experiment), By Application (Hospital, Laboratory, Other) and Regional Forecast to 2034
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
FUNGAL INFECTION DIAGNOSIS MARKET OVERVIEW
The global fungal infection diagnosis market size was valued at USD 0.22 billion in 2025 and is expected to reach USD 0.47 billion by 2034, growing at a compound annual growth rate (CAGR) of about 8.92% from 2025 to 2034.
The United States Fungal Infection Diagnosis Market size is projected at USD 0.09 Billion in 2025, the Europe Fungal Infection Diagnosis Market size is projected at USD 0.06 Billion in 2025, and the China Fungal Infection Diagnosis Market size is projected at USD 0.03 Billion in 2025.
The term "fungal infection diagnosis market" refers to the market for diagnostic tests and equipment used to find and diagnose fungal infections in patients. Mycoses, commonly referred to as fungal infections, are diseases that affect numerous body parts, such as the skin, nails, respiratory system, and internal organs. They are brought on by different forms of fungus.
Recent years have seen a notable increase in the size of the worldwide market for diagnosing fungi. This can be attributable to a number of causes, including the rising incidence of fungus infections, increased awareness of the need of early detection, and improvements in diagnostic technology.
KEY FINDINGS
- Market Size and Growth: Global market grew by approximately 40% share contribution from North America and ~25% from Asia Pacific in recent years
- Key Market Driver: Rising fungal infection prevalence and immunocompromised patient base grew by around 5% annually in reported data
- Major Market Restraint: Survey found roughly 45% of healthcare professionals report knowledge gaps limiting effective diagnosis adoption rates
- Emerging Trends: Molecular diagnostics techniques such as PCR and NGS adoption share rose to about 30% of total diagnostic methods
- Regional Leadership: In 2023 North America held ~40% of total global market share, with Asia Pacific ~25% and Europe ~20%
- Competitive Landscape: Top diagnostic method segments: Galactomannan test ~45% share, (1‑3)-β‑D‑glucan ~35% of type-based usage
- Market Segmentation: Galactomannan test segment accounts for ~45%, (1‑3)-β‑D‑glucan experiment around ~35% of diagnostic method share
- Recent Development: Diagnostic laboratories share in applications rose to ~30% from earlier lower base, hospitals ~50%, clinics ~20%
COVID-19 IMPACT
Disruption in Healthcare Services to Limit the Market Demands
Priorities in healthcare have significantly changed in response to the pandemic in favor of treating COVID-19 victims. Due to this change, less time and money are now being spent on diagnosing and treating other illnesses, such as fungi infections. Lockdown processes, overburdened healthcare systems, and the demand for social isolation have interfered with standard healthcare services, including diagnosing fungus infections. There has been a significant drop in the detection of fungal infections as a result of several non-essential medical treatments and visits being delayed or canceled.
LATEST TRENDS
Automation and Artificial Intelligence to Augment the Market Growth
In diagnostic labs, the identification of a fungal infection is streamlined via the use of automation and artificial intelligence (AI) technology. Through the use of these technologies, the diagnostic process may be sped up and human error reduced while also helping to comprehend the findings of diagnostic tests. To increase precision and efficacy in the diagnosis of fungi, machine learning algorithms and AI-based image analysis methods are being investigated. Due to their rising prevalence and the advent of drug-resistant forms, fungus infections have drawn increased attention in recent years. Improvements in diagnostic procedures have resulted from a greater understanding among medical experts. The development of new diagnostic techniques, the investigation of fresh biomarkers, and the advancement of our knowledge of fungal pathogenesis are also the main areas of continuing study.
FUNGAL INFECTION DIAGNOSIS MARKET SEGMENTATION
By Type Analysis
By type, market is segmented into galactomannan test and (1 to 3)-β-D-glucan experiment. The galactomannan test segment will dominate the market in the coming years.
By Application Analysis
Based on applications, the market is classified into Hospital, Laboratory And Others. The hospital segment will lead the global share through forecast period.
DRIVING FACTORS
Technological Advancements in Diagnostic Techniques to Push the Market
Around the world, fungus infections are more frequent. The prevalence of antibiotics and immunosuppressive medications, as well as other factors like an aging population, an increase in the number of immunocompromised individuals (such those with HIV/AIDS or receiving chemotherapy), and an increase in the number of elderly people are all associated with an increased risk of developing fungi. The need for precise and reliable diagnostic techniques to detect and control these illnesses is a result of this. The identification and diagnosis of fungal infections have substantially improved because to developments in diagnostic technology. Faster and more precise diagnosis of fungal diseases has been made possible by innovations like molecular diagnostics, next-generation sequencing (NGS), and point-of-care testing. The effectiveness and efficiency of diagnosing a fungal infection are improved by these developments, which stimulates market expansion.
Increased Awareness and Early Diagnosis to Boost the Market Demands
The significance of early identification and rapid treatment of fungi infections is becoming more and more well-known among medical experts and the general population. The outcomes of patients are improved when infections are detected early and prevented from spreading. Consequently, there is an increasing need for effective diagnostic tools and assays that can swiftly and precisely detect fungal diseases. Research & development expenditures in the market for diagnosing fungi are rising across the board, in both the public and commercial sectors. Development of new biomarkers, diagnostic tools, and treatment plans for fungi infections are the goals of these initiatives. Growth in the market is driven by efforts to increase diagnostic precision, responsiveness, and accessibility.
RESTRAINING FACTORS
Lack of Awareness and Education to Slow the Market Growth
Despite being widespread, fungus infections frequently go undiagnosed or are incorrectly diagnosed because of a lack of understanding and information among medical experts and the general population. This may reduce the demand for goods used in the diagnosis of fungal infections and restrain market expansion. The identification of fungi may be difficult in areas with little access to medical resources, such as diagnostic laboratories and skilled workers. The market's expansion may be constrained by a lack of resources and infrastructure. Particularly in impoverished nations or areas with few healthcare resources, several diagnostic tests for fungi infections might be pricey. Healthcare providers and patients may be reluctant to use these tests due to the high cost, which would limit market growth.
-
Request a Free sample to learn more about this report
FUNGAL INFECTION DIAGNOSIS MARKET REGIONAL INSIGHTS
North American Market to Grow Exponentially with the Forecasted Period
Mycoses, also known as fungal infections, are brought on by different fungi and can damage the skin, nails, respiratory system, and internal organs, among other sections of the body. Accurate and timely diagnosis of fungal infections is essential for managing and treating them properly.
The healthcare system in this area is well developed, and modern diagnostic tools are widely used. The market for diagnosing fungal infections in North America is expanding as a result of the existence of significant market players, academic institutions, and healthcare facilities.
KEY INDUSTRY PLAYERS
Key Players Focus on Partnerships to Gain a Competitive Advantage
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.
List of Top Fungal Infection Diagnosis Companies
- ASSOCIATES OF CAPE COD (U.S.)
- BioRad (U.S.)
- IMMY (U.S.)
- Beijing Jinshanchuan (China)
- Danna Biological (China)
- Zhanjiang A & C Biological Ltd. (China)
REPORT COVERAGE
The market research study examines the worldwide market in detail, focusing on important elements such as leading players, product/services or type, and leading end-use applications. Aside from that, the research analyses major advancements and provides insights into lighting market trends. In addition to the causes indicated above, the paper includes a number of other factors that have contributed to recent growth.
Attributes | Details |
---|---|
Market Size Value In |
US$ 0.22 Billion in 2025 |
Market Size Value By |
US$ 0.47 Billion by 2034 |
Growth Rate |
CAGR of 8.92% from 2025 to 2034 |
Forecast Period |
2025-2034 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The fungal infection diagnosis market is expected to touch USD 0.47 billion by 2034.
The fungal infection diagnosis market is expected to exhibit a CAGR of 8.92% over 2034.
The driving factors of the market are technological advancements in diagnostic techniques and increased awareness and early diagnosis.
Era Biology Group, Zhanjiang A and C Biological Ltd., Dynamiker Biotechnology (Tianjin) Co., Ltd., Bio-Rad Laboratories, Inc., IMMY, Associates of Cape Cod, Inc., Fujifilm Corporation are some of the key market players in the fungal infection diagnosis market.
The fungal infection diagnosis market is expected to be valued at 0.22 billion USD in 2025.
The key market segmentation, which includes by type (Galactomannan Test, (1 to 3)-?-D-glucan Experiment), by application (Hospital, Laboratory, Other).